glp-1 anorexia access a problem for people with eating disorders Implications of GLP-1 medications for

Because the medication has a half-life of about seven days, it stays in your bloodstream at a relatively stable level throughout the week

Maintaining weight loss after tirzepatide requires deliberate strategies: established exercise habits, protein-prioritized nutrition, and in some cases, transitioning to a lower maintenance dose rather than stopping completely

In 2023 Lilly published results of its phase 2 trial for orforglipron, a once-daily oral drug which achieved up to 14.7% mean weight reduction at 36 weeks, and Pfizer has completed phase 2 trial for its oral drug danuglipron and is now optimising the formulation

Heidenreich PA, Bozkurt B, Aguilar D, et al

Will hunger returnstronger, or stranger